AB9604
Anti-Semaphorin 3A Antibody, central region
Chemicon®, from rabbit
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human, rat
manufacturer/tradename
Chemicon®
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SEMA3A(10371)
Specificity
It is expected that the antibody will also react with mouse.
Semaphorin 3A. The immunogen sequence has low homology with other semaphorin family members.
Immunogen
Synthetic peptide from the central region of human semaphorin 3A.
Application
Anti-Semaphorin 3A Antibody, central region detects level of Semaphorin 3A & has been published & validated for use in WB.
Western blot: 1:1,000 on neonatal rat brain and recombinant human Semaphorin 3A/Fc chimera (95/125 kDa). The antibody reacts with the ~95 kDa protein. The suggested antibody diluent is PBS containing 5% non-fat milk and 0.04% Tween 20.
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
Physical form
Liquid in PBS containing 50% glycerol, 1 mg/mL BSA and 0.05% sodium azide.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Haynes Shek Hei Yuan et al.
Oncotarget, 9(32), 22618-22630 (2018-06-02)
One hallmark of cancer is its ability to recruit a vascular supply to support rapid growth. Suppression of angiogenesis holds potential as a second-line or adjuvant therapy to stunt cancer growth, progression, metastasis, and post-resection regeneration. To begin to test
Transmembrane proteoglycans syndecan-2, 4, receptor candidates for the impact of HGF and FGF2 on semaphorin 3A expression in early-differentiated myoblasts.
Do, MK; Shimizu, N; Suzuki, T; Ohtsubo, H; Mizunoya, W; Nakamura, M; Sawano, S; Furuse et al.
Physiological Reports null
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service